On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

An earlier FTC report published in July 2024 argued that the six largest PBMs were effectively running a monopoly that gave them enormous power over the price of medicines and allowed them to ...

Finally, blaming the pharmaceutical industry for high drug costs has historically been PBMs’ go-to defense. In a rebuttal to the FTC report issued in the summer, the PCMA criticized the ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs.

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...